HERTFORDSHIRE, England, and
PITTSBURGH, Sept. 27, 2019 /PRNewswire/ -- Mylan N.V.
(NASDAQ: MYL) today announced that it has finalized a previously
disclosed civil settlement with the U.S. Securities and Exchange
Commission ("SEC"). On July 29, 2019,
the Company disclosed in its public filings that it had reached an
agreement-in-principle with the SEC's Division of Enforcement to
settle the matter. The matter primarily concerns historical
disclosures and accrual related to the U.S. Department of Justice's
civil investigation concerning the classification of EpiPen® and
EpiPen Jr® Auto-Injectors for purposes of the Medicaid Drug Rebate
Program. Today's settlement fully resolves the SEC's investigation.
Pursuant to the agreement with the SEC, Mylan neither admits nor
denies the SEC's allegations, has consented to the entry of a final
judgment, and will pay $30 million, which previously has been
fully reserved.
Mylan believes at this time, taking all other matters into
consideration, that this settlement is the right course of action
for the Company. The Company continues to be committed to the
highest levels of integrity with respect to all aspects of its
business operations, including its public filing disclosures and
communications with investors.
About Mylan
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
View original
content:http://www.prnewswire.com/news-releases/mylan-finalizes-previously-disclosed-settlement-with-us-securities-and-exchange-commission-300926920.html
SOURCE Mylan N.V.